Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Some physicians who value collective bargaining remain concerned that patient services could suffer, but unionization can be driven by a focus on improving care.
AMA J Ethics. 2020;22(3):E193-200. doi:
10.1001/amajethics.2020.193.
Martin Bricknell, PhD, David Whetham, PhD, Richard Sullivan, PhD, and Peter Mahoney, PhD
International humanitarian law obliges clinicians to coordinate with local civilian, military, and nongovernment organizations, and implementation isn't easy.
AMA J Ethics. 2022;24(6):E472-477. doi:
10.1001/amajethics.2022.472.